Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3567
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Đăng, N. V., & Hoa, L. T. (2025). 26. Prognostic factors affecting the outcomes of consolidation radiotherapy for stage IVB nasopharyngeal carcinoma at Vietnam National Cancer Hospital. Journal of Medical Research, 192(7), 240-250. https://doi.org/10.52852/tcncyh.v192i7.3567

26. Prognostic factors affecting the outcomes of consolidation radiotherapy for stage IVB nasopharyngeal carcinoma at Vietnam National Cancer Hospital

Nguyen Van Dang, Le Thi Hoa

Main Article Content

Abstract

This study was conducted to evaluate factors related to the outcomes of consolidation radiotherapy in stage IVB nasopharyngeal carcinoma (NPC). A retrospective descriptive analysis was performed on 60 patients with stage IVB NPC who received consolidation radiotherapy following chemotherapy at Vienam National Cancer Hospital from January 2017 to December 2024. The median follow-up time was 21.9 months. The 12-month progression-free survival (PFS) and overall survival (OS) rates were 81.7% and 93.3%, respectively. Liver metastasis and metastasis involving two or more organs were associated with poor response to consolidative radiotherapy. Multivariate logistic regression analysis identified both factors as independent prognostic factors for treatment response (p < 0.05). However, no statistically significant association was found between metastatic characteristics and survival outcomes (p > 0.05).

Article Details

Keywords

Nasopharyngeal carcinoma, distant metastasis, consolidation radiotherapy, prognostic factors

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
2. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2016; 388(10054): 1883-1892. doi:10.1016/S0140-6736(16)31388-5.
3. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. The Lancet. 2019; 394(10192): 64-80. doi:10.1016/S0140-6736(19)30956-0.
4. Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021; 32(4): 452-465. doi:10.1016/j.annonc.2020.12.007.
5. National Comprehensive Cancer Network Head and Neck Cancers, version 2.2025. Accessed April 01, 2025. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
6. You R, Liu YP, Huang PY, et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncology. 2020; 6(9): 1345-1352. doi:10.1001/jamaoncol.2020.1808.
7. Lin S, Tham IWK, Pan J, Han L, Chen Q, Lu JJ. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol. 2012; 35(5): 474-479. doi:10.1097/COC.0b013e31821a9452.
8. Rusthoven CG, Lanning RM, Jones BL, et al. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017; 124(1): 139-146. doi:10.1016/j.radonc.2017.03.019.
9. Chen MY, Jiang R, Guo L, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013; 32(11): 604-613. doi:10.5732/cjc.013.10148.
10. Hui EP, Leung SF, Au JSK, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004; 101(2): 300-306. doi:10.1002/cncr.20358.
11. Li WZ, Hua X, Xie DH, et al. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy. ESMO Open. 2021; 6(1). doi:10.1016/j.esmoop.2020.100004.
12. Xu H, Lu L, Lu T, et al. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. Head Neck. 2021; 43(9): 2602-2610. doi:10.1002/hed.26726.
13. Zeng F, Lu T, Xie F, et al. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study. Transl Oncol. 2021; 14(11): 101187. doi:10.1016/j.tranon.2021.101187.
14. Yang JH, Sun XS, Xiao BB, et al. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy. BMC Cancer. 2021; 21: 534. doi:10.1186/s12885-021-08246-0.
15. Pan JJ, Mai HQ, Ng WT, et al. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncology. 2024; 10(12): 1627-1635. doi:10.1001/jamaoncol.2024.4354.
16. Lu TZ, Zeng F juan, Hu YJ, et al. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma. Cancer Medicine. 2023; 12(24): 22091-22102. doi:10.1002/cam4.6816.
17. Li WZ, Lv SH, Liu GY, et al. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. Int J Radiat Oncol Biol Phys. 2021; 109(1): 120-130. doi:10.1016/j.ijrobp.2020.08.045.